# Regulatory Digest: Rescheduling Marijuana and Controlled Substances > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/controlled-substances-rescheduling-2026/ > **Published:** 2026-03-06T12:17:38-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T12:00:36-04:00 > **Clinical Summary:** Explore the controlled substances rescheduling 2026 and its impact on clinical research and marijuana regulations. --- ✦ New ## Regulatory updates (higher clinical relevance) - **(100)** [regulations.gov] [Schedules of Controlled Substances: Rescheduling of Marijuana](https://www.regulations.gov/document/DEA-2024-0059-0001) - **(85)** [regulations.gov] [Bulk Manufacturer-Royal Emerald (2024-11786) DEA1368](https://www.regulations.gov/document/DEA-2024-0060-0001) - **(85)** [regulations.gov] [Exempt Chemical Preparations May 2024 (2024-10465) – DEA372](https://www.regulations.gov/document/DEA-2022-0002-0006) - **(85)** [regulations.gov] [Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224](https://www.regulations.gov/document/DEA-2023-0096-0001) - **(78)** [regulations.gov] [Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425](https://www.regulations.gov/document/DEA-2024-0112-0001) - **(78)** [regulations.gov] [Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I](https://www.regulations.gov/document/DEA-2024-0026-0001) Digest-Level Clinical Commentary Dr. Caplan’s Take Clinical Reflection The pending rescheduling of marijuana from Schedule I signals a potential watershed moment for evidence generation in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), as a lower scheduling classification could facilitate legitimate FDA-regulated [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and pharmacokinetic studies that have been constrained by current restrictions. This regulatory shift, combined with emerging manufacturer oversight frameworks, suggests we may finally acquire the rigorous safety and efficacy data needed to move beyond anecdotal reports and toward evidence-based dosing protocols and patient selection criteria for conditions like [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) and chemotherapy-induced nausea. As clinicians, we should prepare now to translate whatever research opportunities emerge into practical clinical guidance, while maintaining appropriate skepticism about unsubstantiated claims until prospective data supports therapeutic claims. Clinical Perspective Clinical Perspective The rescheduling of marijuana represents a significant shift in the federal regulatory landscape that has direct implications for [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and evidence generation. This regulatory change may facilitate more rigorous pharmacological studies and [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/), which are essential for establishing dosing standards, efficacy, and safety profiles in therapeutic applications. Clinicians should anticipate evolving evidence-based guidelines as research accessibility improves and more standardized manufacturing oversight occurs. Regulatory Policy[Clinical Research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/)Controlled SubstancesManufacturingScheduling πŸ’¬ Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan β†’](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion β†’](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Regulatory+Digest+2026-03-06+%40drcaplan&url=) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=) [πŸ¦… Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Regulatory+Digest+2026-03-06+--+via+%40drcaplan.bsky.social+) [πŸ“· Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [πŸ“ Read more on Substack](https://substack.com/@doctorapproved) [πŸ”” Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - Daily Digest 2026-03-07 - Daily Digest 2026-03-07 - [Regulatory Digest 2026-03-06](https://cedclinic.com/regulatory-digest-2026-03-09/) Further Reading Evidence Watch[`Cannabinoid Clinical Trials: CBD Cortical Excitability Study`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Federal Marijuana reclassification could reshape medical research and cannabis industry](https://cedclinic.com/federal-marijuana-rescheduling-medical-research-clinical-impact/) Learn how federal marijuana rescheduling may transform [medical research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) and the cannabis industry landscape. [Read More](https://cedclinic.com/federal-marijuana-rescheduling-medical-research-clinical-impact/) [Reclassification of marijuana opens doors for much-needed medical research … – The Conversation](https://cedclinic.com/cannabis-reclassification-medical-research-opportunities-schedule-iii/) Discover how marijuana reclassification can facilitate essential [medical research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) and clinical trials. [Explore Article](https://cedclinic.com/cannabis-reclassification-medical-research-opportunities-schedule-iii/) [Justice Department, DEA ordered to reclassify state-licensed medical cannabis as less … – Maui Now](https://cedclinic.com/federal-cannabis-reclassification-clinical-implications/) Understand the clinical impact of federal cannabis reclassification on patients and healthcare providers. [Learn More](https://cedclinic.com/federal-cannabis-reclassification-clinical-implications/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR Β§ 164.514(b)) and criteria for secondary research exemption under 45 CFR Β§ 46.104(d)(4).